CytomX Therapeutics is an early stage, privately-funded biotechnology company developing Probodiesâ„¢, proteolytically-activated antibodies. Probodies, by their ability to site-direct the activity of antibodies, will result in an improved therapeutic index for validated targets as well enable the drugging of targets with broad tissue expression. Our mission, alone and with the help of partners, is to provide patients with more effective and less toxic therapies for severe illnesses such as cancer and inflammatory diseases.
Current Team (8)Update
Past Team (5)Update
Funding Rounds (3) - $43.5MUpdate
Board Members and Advisors (5)Update
460 Ward Drive
Santa Barbara, CA 93111